(S) - (+) -Rolipram

(S) - (+) -Rolipram ((+) -Rolipram) is a cyclic AMP (cAMP) -specific phosphodiesterase 4 (PDE4) inhibitor, with an IC50 of 1100 nM. (S) - (+) -Rolipram can suppresse tumor necrosis factor-alpha (TNFα) production by human mononuclear cells[1][2][3].

Product Specifications

CAS Number

[85416-73-5]

Product Name Alternative

(+) -Rolipram; (S) -Rolipram

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/_S_-__addition__-Rolipram.html

Concentration

10mM

Purity

99.96

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1NC[C@H](C2=CC=C(OC)C(OC3CCCC3)=C2)C1

Molecular Formula

C16H21NO3

Molecular Weight

275.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Semmler J, et, al. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells. Int J Immunopharmacol. 1993 Apr;15 (3) :409-13.|[2]Wachtel H. Neurotropic effects of the optical isomers of the selective adenosine cyclic 3',5'-monophosphate phosphodiesterase inhibitor rolipram in rats in-vivo. J Pharm Pharmacol. 1983 Jul;35 (7) :440-4.|[3]Ortmann R, et, al. Rolipram forms a potent discriminative stimulus in drug discrimination experiments in rats. Psychopharmacology (Berl) . 1986;89 (3) :273-7.